Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox for Oxidative Stress in Sickle Cell Disease (TROS)
NCT05392101Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in sickle cell disease (SCD), sponsored by University of Amsterdam. Primary endpoints: Point of Sickling at 8 months and Oxidative stress at 8 months. Started Jul 2021; status: completed.
02
Drugs
deferasirox
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05392101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392101.